How Does Inovio Pharmaceuticals Inc (INO) Stock Rank on Wall Street Friday?

Analysts who follow Inovio Pharmaceuticals Inc (INO) on average expect it to rise 96.95% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns the stock an Analyst Ranking of 31, which means it ranks higher than 31 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating INO a Buy today. Find out what this means to you and get the rest of the rankings on INO!

See Full INO Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Inovio Pharmaceuticals Inc Stock Today?

Inovio Pharmaceuticals Inc (INO) stock has risen 13.18% while the S&P 500 has fallen -0.34% as of 2:30 PM on Friday, Mar 8. INO is higher by $1.19 from the previous closing price of $9.03 on volume of 872,148 shares. Over the past year the S&P 500 is higher by 31.18% while INO has fallen -25.94%. INO lost -$6.09 per share the over the last 12 months. Click Here to get the full Stock Report for Inovio Pharmaceuticals Inc stock.